286MM, Scientist / Associate Scientist, T-cell Development / Off-the-Shelf CAR-T Product Development

Job Code 286MM

Description

Fate’s Cancer Immunotherapy group is seeking a motivated individual with expertise in cancer biology, immunology, cell biology or related field to join a multidisciplinary team dedicated to the discovery of novel off-the-shelf cellular therapeutics for the treatment of cancer and other disorders. The successful candidate will be responsible for the development and optimization of novel engineered lymphoid differentiation protocols, including the derivation of off-the-shelf CAR-T cells, from induced pluripotent stem cells (iPSC) as well as their functional assessment in various tumor models. The candidate must have experience with mammalian cell culture. The candidate will also play a key role in collaborating with top academic institutes to support discovery, manufacturing and clinical trials. This is a full-time position reporting to a Senior Scientist in Cancer Immunotherapy leading several off-the-shelf CART Product Development programs, and is located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 286MM.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.